Sickle cell disease: the price of cure

摘要

In this issue of Blood, the first prospective trial of unrelated donor bone marrow transplantation (BMT) in children with sickle cell disease (SCD), reported by Shenoy et al, is an important step in extending curative therapy to more children with severe disease.(1)